

CURRICULUM VITAE

Richard D. Press, M.D., Ph.D.

Expertise & Experience:

Academic medical center pathologist with extensive experience in diagnostic molecular pathology, as well as clinical and translational research.

Office Address: Oregon Health & Science University (OHSU)
Department of Pathology, L113
3181 SW Sam Jackson Park Rd.
Portland, OR 97201-3098
Tel. 503-494-2317
FAX 503-494-2025
email: pressr@ohsu.edu

(b) (6) [REDACTED]
(b) (6) [REDACTED]
(b) (6) [REDACTED]

[REDACTED]
[REDACTED]

Education:

- (b) (6) -- B.A., Chemistry, Northwestern University, Evanston, IL
- (b) (6) -- Ph.D., Biochemistry, Case Western Reserve Univ., Cleveland, OH
- (b) (6) -- M.D., Medical Scientist Training Program, Case Western Reserve University, Cleveland, OH

Postgraduate Training:

- (b) (6) -- Resident Physician, Department of Pathology & Laboratory Medicine, Hospital of the Univ. of Pennsylvania, Philadelphia, PA
- (b) (6) -- Research Associate, The Wistar Institute, Philadelphia, PA

Academic & Professional Appointments:

- 1991-1993 -- Research Investigator, The Wistar Institute, Philadelphia, PA.
- 1993-1999 -- Assistant Professor of Pathology, Oregon Health Sciences University
- 1993-1999 -- Assistant Professor of Molecular and Medical Genetics, OHSU
- 1994-1999 -- Assistant Professor of Cell & Developmental Biology, OHSU
- 1999-2006 -- Associate Professor, OHSU (Pathology & Genetics departments)
- 1993- -- Director, Molecular Pathology, OHSU Dept of Pathology
- 2002- -- Program Director, Molecular Genetic Pathology fellowship, OHSU
- 2004- -- Medical Director, OHSU Molecular Diagnostics Center
- 2006- -- Professor, OHSU (Pathology & Genetics departments)
- 2010- -- Medical Director, Molecular Diagnostics, OHSU Knight Diagnostic Laboratories

Certification and Licensure:

- 1993- -- Oregon Permanent Medical License (b) (6)
- 1992 -- Diplomate in Clinical Pathology, The American Board of Pathology

2001- -- Board Certified Diplomate in Molecular Genetic Pathology, American Board of Pathology & American Board of Medical Genetics

Professional Affiliations:

- 1993- -- Fellow, College of American Pathologists
- 1994- -- Association for Molecular Pathology
- 1999- -- American Association for Clinical Chemistry
- 2004- -- American Society of Hematology

Teaching Activities:

- 1994- -- Pathology 610, Basic Biology of Disease (for first year medical students), OHSU School of Medicine.
- 1996- -- Supervisor, pathology resident rotations in molecular pathology
- 1997- -- Pathology resident in-service course: Molecular Pathology
- 2002- -- Director of ACGME-accredited fellowship program in Molecular Genetic Pathology

Professional Peer Review:

- 1997- -- Laboratory Inspector, College of American Pathologists, Laboratory Accreditation Program
- 1998-2001 -- Editorial board, *Molecular Diagnosis*
- 1998-2001 -- Editor, "Clinical News Update" section of *Molecular Diagnosis*
- 1999-2010 -- Editorial Board, *Journal of Molecular Diagnostics*
- 2006- -- Ad hoc reviewer for *Blood*
- 2008 -- Member, CDC Special Emphasis (review) Panel for RFA GD-08-001, Genomic Applications in Practice & Prevention (GAPP): Translation Research
- 2008- -- Advisor, Clinical Laboratory Standards Institute (CLSI), Subcommittee on Nucleic Acid Amplification Assays for Molecular Hematopathology

Clinical Activities:

- 1993- -- Staff Physician, OHSU Hospital
- 1993- -- Director, Molecular Pathology Laboratory, OHSU
- 1997- -- Co-Director, DNA Diagnostic Laboratory, OHSU Hospital
- 2004- -- Medical Director, Molecular Diagnostics Center, OHSU
- 2010- -- Director, Molecular Pathology, OHSU Knight Diagnostic Laboratories

National/ International Committees and Awards:

- 1996 - 1998 -- Chairman, Clinical Practice Committee, Assoc. for Molecular Pathology
- 1996 - 1998 -- Executive Council Member, Assoc. for Molecular Pathology
- 2000 - 2001 -- Chairman-elect and Chairman, Genetics section, Assoc. for Molecular Pathology
- 2000 - 2003 -- Executive Council Member, Assoc. for Molecular Pathology
- 2002 - 03 -- Secretary-Treasurer, Assoc. for Molecular Pathology
- 2002 - 03 -- Chair, Publications Committee, Assoc. for Molecular Pathology
- 2002 - 07 -- College of American Pathologists, Biochemical and Molecular Genetics Resource Committee

- 2008 - 2010 -- Co-Chair, Membership & Professional Development committee, Association for Molecular Pathology
- 2010 - 2011 -- College of American Pathologists, Public Health Policy Committee
- 2012 - -- College of American Pathologists, Economic Affairs Committee
- 2013 - -- College of American Pathologists, Biochemical & Molecular Genetics Resource Committee
- 2013- -- Economic Affairs Committee, Association for Molecular Pathology
- 2014- -- Member, Clinical Laboratory Improvement Advisory Committee (CLIAc), Center for Disease Control (CDC)

Research Support:

- 1990-1991 -- Fellow, University of Pennsylvania Cancer Center Training Grant
- 1991-1994 -- Principal Investigator, Clinical Investigator Development Award, NIH, Grant #K08-NS-01551. "Structure & function of myb oncogene in neuronal cells";
- 1994-1995 -- Principal Investigator, Oregon Medical Research Fund Grant. "Induction of lymphomas by overexpression of the myb oncogene".
- 1994-1995 -- Principal Investigator, American Cancer Society grant. "Structural alterations of the MYB oncoprotein determining oncogenicity
- 1995-1997 -- Principal Investigator, American Heart Association Grant. "A common mutation in coagulation factor V as a risk factor for arterial thromboembolism."
- 1995-1997 -- Principal Investigator, Leukemia Research Foundation grant. "Mechanisms of myb-induced hematopoietic cell transformation."
- 1996-2001 -- Principal Investigator, NIH NCI (CA72021) grant. "Mechanisms of pathogenesis by the myb oncoprotein".
- 1998 -- Principal Investigator, American Heart Association. Student Summer Fellowship.
- 1998-1999 -- Sub-project, NIH-NCI Program Project (5P30-CA69533-01A1, Oregon Cancer Center). "Hemochromatosis Gene Mutations, Iron Overload, & Cancer Risk."
- 1998-1999 -- Principal Investigator, American Cancer Society (Oregon Division). "Hemochromatosis Gene Mutations & Cancer Risk."
- 1999-2000 -- Principal Investigator, Bio-Rad Laboratories. "MDx Factor V Leiden validation".
- 1999-2000 -- Roche Diagnostics. "LightCycler detection of genotypes predisposing to common diseases".
- 2000 -2005 -- Co-investigator, NIH-NHLBI grant 3N01HC005189 (PI, Emily Harris), "Iron overload and hereditary hemochromatosis- field center." (HEIRS)
- 2003 - 2005 -- Principal Investigator, NIH NCI grant R21CA095203. "Bcr-Abl RNA levels to monitor ST1571 leukemia therapy."
- 2003-2004 -- Investigator, Roche-Novartis cooperative study, "Standardization of Bcr-Abl RT-PCR quantitation for leukemia minimal residual disease."
- 2003-2004 -- Investigator, Roche Diagnostics, "Factor V Leiden and Prothrombin G20210A genotyping for the detection of thrombophilia."
- 2007 -- Trimgen Corporation. "eQ-PCR Warfarin Genotyping Study".

2010-	--	Principal Investigator, NCI/NIH RFP ST10-1078, "Basic Ordering Agreement in Support of the Clinical Assay Development Network to Facilitate Development & Validation of Clinical Assays".
2012		Cepheid: Comparative Evaluation of the Cepheid Xpert® BCR-ABL Monitor Assays
2012-		Asuragen: "BCR-ABL Feasibility Study"
2013-		Ipsogen/Qiagen: JAK2 V617F FDA clinical trial
2013		Sequenom: "Factor V Leiden / Prothrombin FDA clinical trial"

PUBLICATIONS:

Original Papers:

1. Arnett MA, Venkatasubramaniam KG, McIver RT, Fukuda EK, Bordwell FG, **Press RD**: Stabilization of the monoanion of 1,8-Diaminonaphthalene by intramolecular hydrogen bonding. A novel case of amide ion homoconjugation in a superbase solution. *J Amer Chemical Soc* 104: 325-326, 1982.
2. **Press RD**, Samols D, Goldthwait DA: Expression and stability of c-sis RNA in human glioblastoma cells. *Biochemistry* 27: 5736-5741, 1988.
3. **Press RD**, Misra A, Gillaspy G, Samols D, Goldthwait DA: Control of the expression of c-sis mRNA in human glioblastoma cells by phorbol ester and transforming growth factor-b. *Cancer Research* 49: 2914-2920, 1989.
4. **Press RD**, Misra A, Mapstone TB, Goldthwait DA: Major structural alterations of the c-sis gene are not observed in a series of tumors of the human central nervous system. *J Neuro Oncology* 7: 345-356, 1989.
5. **Press RD** and Wilding P: Effect of glycation of low density lipoprotein on the immunologic determination of apolipoprotein B. *Clinical Chemistry* 35: 2219-2223, 1989.
6. **Press RD**, Jacobberger J, Samols D, Goldthwait DA: The cell cycle dependence of c-sis gene expression: artifactual conclusions in cells prepared by chemical but not physical techniques. *Cell Tissue Kinetics*. 23: 299-312, 1990.
7. **Press RD**, Kim A, Ewert DL, and Reddy EP: Transformation of chicken myelomonocytic cells by a retrovirus expressing the v-myb oncogene from the long terminal repeats of avian myeloblastosis virus but not Rous sarcoma virus. *J. Virology* 66: 5373-5383, 1992.
8. **Press RD**, Reddy EP, and Ewert DL. Overexpression of C-terminally but not N-terminally truncated myb induces fibrosarcomas: a novel non-hematopoietic target cell for the myb oncogene. *Mol Cell Biol* 14: 2278-2290, 1994.
9. **Press RD** and Goodnight S. Predisposition to thrombosis by a factor V mutation causing hereditary resistance to activated protein C. *West. J. Med.* 162: 5-7, 1995.

10. Liu X-Y, Nelson D, Grant C, Morthland V, Goodnight S, and **Press RD**. Molecular detection of a common mutation in coagulation factor V causing thrombosis via hereditary resistance to activated protein C. *Diag. Mol. Path.* 4: 191-197, 1995
11. **Press RD**, Wisner, TW, and Ewert DL. Induction of B cell lymphomas by overexpression of a myb oncogene truncated at either terminus. *Oncogene* 11:525-535, 1995.
12. **Press RD**, Liu X-Y, Beamer N, and Coull B. Ischemic stroke in the elderly: role of the common factor V mutation causing resistance to activated protein C. *Stroke* 27 : 44-48, 1996.
13. Flora K, Schiele M, Benner K, Montanaro A, Johnston W, Whitman R, and **Press RD**. An outbreak of acute hepatitis C among recipients of intravenous immunoglobulin. *Annals Allergy, Asthma, & Immunology* 76: 160-162, 1996.
14. Goodnight SH, Deloughery TG, and **Press RD**. Recognition and management of the hypercoagulable states: a decade of change. *J. Thrombosis & Thrombolysis*, 2: 271-74, 1996.
15. Deloughery TG, Evans A, Sadeghi A, McWilliams J, Henner WD, Taylor LM, **Press RD**. Common mutation in methylenetetrahydrofolate reductase: correlation with homocysteine metabolism and late onset vascular disease. *Circulation* 94: 3074-3078, 1996.
16. Ocal I, Sadeghi A, and **Press RD**. Risk of venous thrombosis in carriers of a common mutation in the homocysteine regulatory enzyme methylene tetrahydrofolate reductase (MTHFR). *Molecular Diagnosis* 2: 61-68, 1997.
17. **Press RD**, Flora K, Gross C, Rabkin J, and Corless C. Hepatic iron overload: direct HFE (HLA-H) mutation analysis vs quantitative iron assays for the diagnosis of hereditary hemochromatosis. *Am J Clin Path* 109: 577-584, 1998.
18. Lutz CT, Foster PA, Noll WW, Voelkerding KV, **Press RD**, McGlennen RC, Kirschbaum NE. Multicenter evaluation of PCR methods for the detection of factor V Leiden (R506Q) genotypes. *Clinical Chemistry* 44: 1356-8, 1998.
19. Cotler SJ, Bronner MP, **Press RD**, Carlson TH, Perkins JD, Emond MJ, and Kowdley KV. End-stage liver disease without hemochromatosis associated with elevated hepatic iron index. *J Hepatology* 29: 257-262, 1998.
20. **Press RD**, Beamer N, Evans A, DeLoughery T, & Coull BM. Role of A Common Mutation in the Homocysteine-Regulatory Enzyme Methylenetetrahydrofolate Reductase (MTHFR) in Ischemic Stroke. *Diagn Mol Path* 8: 54-58, 1999.
21. **Press RD**. Hereditary hemochromatosis: impact of molecular (and iron-based) testing on the diagnosis, treatment, and prevention of a common, chronic disease. *Arch Pathol Lab Med* 123: 1053-1059, 1999.
22. Gomez PS, Parks S, Ries R, Tran TC, Gomez PF, & **Press RD**. Polymorphism in intron 4 of HFE does not compromise haemochromatosis mutation results. *Nature Genetics* 23: 271-2, 1999.

23. Edman, C. F., Mehta, P., **Press, R. D.**, Spargo, C. A., Walker, G. T., and Nerenberg, M. Pathogen analysis and genetic predisposition testing using microelectronic arrays and isothermal amplification. *J Investig Med* 48: 93-101, 2000.
24. Egan RA, Kuy JM, **Press RD**, Lutsep HL. Lack of prothrombin gene mutation in young stroke patients. *J. Stroke Cerebrovasc Disease* 9: 229-231, 2000.
25. Parks SB, Popovich BW, & **Press RD**. Real-Time PCR with Fluorescent Hybridization Probes for the Detection of Prevalent Mutations Causing Common Thrombophilic and Iron Overload Phenotypes. *Am J Clin Path* 115: 439-47, 2001.
26. Reyes AA, Ugozzoli LA, Lowery JD, Breneman JW, Hixson C, **Press RD**, & Wallace RB. Linked linear amplification: a new method for the amplification of DNA. *Clin Chem* 47: 31-40, 2001.
27. **Press RD**, Bauer KA, Kujovich JL, and Heit JA. Clinical utility of factor V Leiden (R506Q) testing for the diagnosis and management of thromboembolic disorders. *Archives of Pathology & Lab Medicine* 126: 1304-1318, 2002.
28. McDonald CJ, Huff SM, Suico JG, et al. LOINC, a universal standard for identifying laboratory observations: a 5 year update. *Clin Chem* 49: 624-633, 2003.
29. McLaren CE, Barton JC, Adams PC, et al. Hemochromatosis and Iron Overload Screening (HEIRS) Study Design for an Evaluation of 100,000 Primary Care-Based Adults. *American J Med Science* 325: 53-62, 2003.
30. Hong KM, Najjar H, Hawley M, and **Press RD**. Quantitative real-time PCR with automated sample preparation for diagnosis and monitoring of CMV infection in bone marrow transplant patients. *Clin Chem* 50: 846-56, 2004.
31. Sekhon H, **Press RD**, Schmidt W, Hawley M, Rader A. Identification of cytomegalovirus in a liquid-based gynecologic sample using morphology, immunohistochemistry and DNA real-time PCR detection. *Diagnostic Cytopathology*, 30: 411, 2004.
32. Adams PC, Reboussin DM, Leiendecker-Foster, et al. Comparison of the unsaturated iron binding capacity with transferrin saturation as a screening test to detect C282Y homozygotes for hemochromatosis in 101,168 participants in the Hemochromatosis and Iron Overload Screening (HEIRS) Study. *Clin Chem* 51: 1048-52, 2005.
33. Adams PC, Reboussin DM, Barton JC, et al (for the HEIRS Study Investigators). Hemochromatosis and Iron-Overload Screening in a Racially Diverse Population. *New Engl J Med* 352: 1769-78, 2005.
34. **Press RD**, Love Z, Tronnes A, et al. Bcr-Abl RNA Levels At and After the Time of a Complete Cytogenetic Remission (CCR) Predict the Duration of CCR In Imatinib-Treated CML Patients. *Blood* 107: 4250-4256, 2006.
35. Rivers CA, Barton JC, Gordeuk VR, Acton RT, Speechley MR, Snively BM, Leiendecker-Foster C, **Press RD**, Adams PC, McLaren GD, Dawkins FW, McLaren CE, Reboussin DM; for the Hemochromatosis and Iron Overload Screening Study. Association of ferroportin Q248H polymorphism with elevated levels of serum ferritin in African

- Americans in the Hemochromatosis and Iron Overload Screening (HEIRS) Study. *Blood Cells Mol Dis.* 38: 247-252 (2007).
36. Adams PC, Reboussin DM, **Press RD**, Barton JC, Acton RT, Moses GC, Leiendecker-Foster C, McLaren GD, Dawkins FW, Gordeuk V, Lovato L, Eckfeldt JH. Biological variability of transferrin saturation and unsaturated iron binding capacity. *American Journal of Medicine*, 120 (11), 999.e1-7, 2007.
 37. Sherbenou DW, Wong MJ, Humayun A, McGreevey LS2, Harrell P, Yang R, Mauro M, Heinrich MC, **Press RD**, Druker BJ, & Deininger MW. Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib. *Leukemia* 21: 489-493, 2007.
 38. James C Barton, Ronald T Acton, Catherine Leiendecker-Foster, Laura Lovato, Paul C Adams, Gordon D McLaren, John H Eckfeldt, Christine E McLaren, David M Reboussin, Victor R Gordeuk, Mark R Speechley, Jacob A Reiss, **Richard D Press**, Fitzroy W Dawkins. HFE C282Y homozygotes ages 25-29 years at HEIRS study initial screening. *Genetic Testing* 11 (3): 269-275, 2007.
 39. Ronald T. Acton, Beverly M. Snively, James C. Barton, Christine E. McLaren, Paul C. Adams, Stephen S. Rich, John H. Eckfeldt, **Richard D. Press**, Phyllis Sholinsky, Catherine Leiendecker-Foster, Gordon D. McLaren, Mark R. Speechley, Emily L. Harris, Fitzroy W. Dawkins, Victor R. Gordeuk. A genome-wide linkage scan for iron phenotype quantitative trait loci: The HEIRS Family Study. *Clinical Genetics* 71: 518-29, 2007.
 40. **Press RD**, Galderisi C, Yang R, Rempfer C, Willis SG, Mauro MJ, Druker BJ, and Deininger MWN. A Half-Log Increase in BCR-ABL RNA Predicts a Higher Risk of Relapse in Patients with Chronic Myeloid Leukemia with an Imatinib-Induced Complete Cytogenetic Response (CCR). *Clin Cancer Research*, 13 (20): 6136-6143, 2007.
 41. Muller MC, Saglio G, Lin F, Pfeifer H, **Press RD**, Tubbs RR, Paschka P, Gottardi E, O'Brien SG, Ottmann OG, Stockinger H, Wieczorek L, Merx K, Konig H, Schwindel U, Hehlmann R, & Hochhaus A. An international study to standardize the detection and quantitation of BCR-ABL transcripts from stabilized peripheral blood preparations by quantitative RT-PCR. *Haematologica* 92: 970-973, 2007.
 42. Jennifer Laudadio, Michael WN Deininger, Michael J Mauro, Brian J Druker, and **Richard D Press**. An Intron-Derived Insertion-Truncation Mutation in the BCR-ABL Kinase Domain in CML Patients Undergoing Kinase Inhibitor Therapy. *J. Molec Diagn*, 10: 177-180, 2008.
 43. James C. Barton, Ronald T. Acton, Catherine Leiendecker-Foster, Laura Lovato, Paul C. Adams, John H. Eckfeldt, Christine E. McLaren, Jacob A. Reiss, Gordon D. McLaren, David M. Reboussin, Victor R. Gordeuk, Mark R. Speechley, **Richard D. Press**, & Fitzroy W. Dawkins. Characteristics of participants with self-reported hemochromatosis or iron overload at HEIRS Study initial screening. *Am J Hematol* 83 (2): 126-132, 2008.
 44. James C. Barton, Catherine Leiendecker-Foster, David M. Reboussin, Paul C. Adams, Ronald T. Acton, John H. Eckfeldt, & the Hemochromatosis and Iron Overload Screening Study Research Investigators. Thyroid-Stimulating Hormone and Free Thyroxine Levels in

- Persons with HFE C282Y Homozygosity, a Common Hemochromatosis Genotype: The HEIRS Study. *Thyroid* 18 (8): 831-838, 2008.
45. DW Sherbenou, O Hantschel, L Turaga, I Kaupe, S Willis, T Bumm, **RD Press**, G Superti-Furga, BJ Druker, and MW Deininger. Characterization of BCR-ABL deletion mutants from patients with chronic myeloid leukemia. *Leukemia* 22: 1184-90, 2008.
 46. S Branford, L Fletcher, NCP Cross, MC Müller, A Hochhaus, D-W Kim, J Radich, G Saglio, F Pane,⁷ S Kamel-Reid, YL Wang, **RD Press**, K Lynch, Z Rudzki, J M Goldman, T Hughes. Desirable performance characteristics for *BCR-ABL* measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. *Blood* 112: 3330-3338, 2008.
 47. Quigley NB, Henley DC, Hubbard RA, Laudadio J, **Press RD**. ABL kinase domain pseudoexon insertion is not uncommon in BCR-ABL transcripts. *J Mol Diagn.* 10: 475-476, 2008.
 48. McLaren GD, McLaren CE, Adams PC, Barton JC, Reboussin DM, Gordeuk VR, Acton RT, Harris EL, Speechley MR, Sholinsky P, Dawkins FW, Snively BM, Vogt TM, Eckfeldt JH; & Hemochromatosis and Iron Overload Screen (HEIRS) Study Research Investigators. Clinical manifestations of hemochromatosis in HFE C282Y homozygotes identified by screening. *Can J Gastroenterol.* 22(11): 923-30, 2008.
 49. Dan Jones, Suzanne Kamel-Reid, David Bahler, Henry Dong, Kojo Elenitoba-Johnson, **Richard Press**, Neil Quigley, Paul Rothberg, Dan Sabath, David Viswanatha, Karen Weck and James Zehnder. Laboratory practice guidelines for detecting and reporting BCR-ABL drug resistance mutations in chronic myelogenous leukemia and acute lymphoblastic leukemia. *J Mol Diagn* 11: 4-11, 2009.
 50. DW Wolff, DL Heaney, PD Neuwald, KA Stellrecht, & **RD Press**. Multi-site PCR-based CMV Viral Load Assessment - Assays Demonstrate Linearity and Precision, but Lack Numeric Standardization. *J Mol Diagn*, 11: 87-92, 2009
 51. **Richard D. Press**, Stephanie G. Willis, Jennifer Laudadio, Michael J. Mauro, and Michael W. N. Deininger. Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib. *Blood* 114: 2598-2605, 2009.
 52. James C. Barton, Susie A. LaFreniere, Catherine Leiendoeker-Foster, Honggui Li, Ronald T. Acton, **Richard D. Press**, and John Eckfeldt. HFE, SLC40A1, HAMP, HJV, TFR2, and FTL mutations detected by denaturing high-performance liquid chromatography after iron phenotyping and HFE C282Y and H63D genotyping in 785 HEIRS Study participants. *Am J Hematology*, 84: 710-714, 2009.
 53. **Richard D. Press**. Major Molecular Response in CML Patients Treated with Tyrosine Kinase Inhibitors: the Paradigm for Monitoring Targeted Cancer Therapy. *The Oncologist* 15: 744-749, 2010.
 54. Daniel W Sherbenou, Oliver Hantschel, Ines Kaupe, Stephanie Willis, Thomas Bumm, Lalita P Turaga, Thoralf D Lange, Kim-Hien D Dao, **Richard D Press**, Brian J Druker,

- Giulio J Superti-Furga, and Michael W Deininger. BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib. *Blood* 116 (17): 3278-3285, 2010
55. Helen E White, Paul Matejtschuk, Peter Rigsby, Jean Gabert, Feng Lin, Y Lynn Wang, Susan Branford, Martin C. Müller, Nathalie Beaufils, Emmanuel Beillard, Dolors Colomer, Dana Dvorakova, Hans Ehrencrona, Hyun-Gyung Goh, Hakim El Housni, Dan Jones, Veli Kairisto, Suzanne Kamel-Reid, Dong-Wook Kim, Stephen Langabeer, Edmond SK Ma, **Richard D. Press**, Giuliana Romeo, Lihui Wang, Katerina Zoi, Timothy Hughes, Giuseppe Saglio, Andreas Hochhaus, John M. Goldman, Paul Metcalfe, and Nicholas CP Cross. Establishment of the 1st World Health Organization International Genetic Reference Panel for quantitation of *BCR-ABL* mRNA. *Blood* 116 (22): 111-117, 2010.
56. Jennifer Dunlap, Katalin Kelemen, Nicky Leeborg, Rita Braziel, Susan Olson, **Richard Press**, James Huang, Ken Gatter, Marc Loriaux, and Guang Fan. Association of JAK2 mutation status and cytogenetic abnormalities in myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms. *Am J Clin Path* 135:709-719 (2011).
57. Tumor necrosis factor-alpha facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms. Angela G Fleischman, Karl J Aichberger, Samuel B Luty, Thomas GP Bumm, Curtis L Petersen, Shirin Dorototaj, Kavin B Vasudevan, Dorian H LaTocha, Fei Yang, Marc M Loriaux, Heike L Pahl, Richard T. Silver, **Richard D Press**, Anupriya Agarwal, Thomas O'Hare, Brian Druker, Grover C Bagby, and Michael W Deininger. *Blood* 118 (24): 6392-6398, 2011.
58. The BCR-ABL^{35INS} insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia. Thomas O'Hare, Matthew S. Zabriskie, Christopher A. Eide, Anupriya Agarwal, Lauren T. Adrian, Huihong You, Amie S. Corbin, Fei Yang, **Richard D. Press**, Victor M. Rivera, Julie Toplin, Stephane Wong, Michael W. Deininger, and Brian J. Druker. *Blood* 118 (19): 5250-54, 2011.
59. Multiplex high-throughput gene mutation analysis in acute myeloid leukemia. Jennifer Dunlap, Carol Beadling, Andrea Warrick, Tanaya Neff, William H. Fleming, Marc Loriaux, Michael C. Heinrich, Tibor Kovacsics, Katalin Kelemen, Nicky Leeborg, Ken Gatter, Rita M. Braziel, **Richard Press**, Christopher L. Corless, Guang Fan. *Human Pathology* 43, 2167–2176, 2012.
60. Quantitative BCR-ABL1 RQ-PCR fusion transcript monitoring in chronic myelogenous leukemia. Moore FR, Rempfer CB, **Press RD**. *Methods Mol Biol*. 999:1-23, 2013.
61. BCR-ABL PCR Testing in Chronic Myelogenous Leukemia: Molecular Diagnosis for Targeted Cancer Therapy and Monitoring. Martin Luu & **Richard Press**. *Expert Rev Mol Diagn* 13(7):749-762, 2013.
62. Detection of BCR-ABL1 kinase domain mutations causing imatinib resistance in chronic myelogenous leukemia. Moore FR, Yang F, **Press RD**. *Methods Mol Biol*. 999:25-39, 2013.

63. BCR-ABL1 RT-qPCR for Monitoring the Molecular Response to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia. **Press RD**, Kamel-Reid S, Ang D. *J Mol Diagn*. 15(5):565-76, 2013.
64. Clinical Implementation of Next-Generation Sequencing. **Press RD**. *Clin Adv Hematol Oncol* 12(4), 263-265, 2014.

Editorials, & Book Chapters

1. **Press, RD**, and Deloughery TG: Hemochromatosis: a common (yet preventable) chronic disease. Oregon Health Division *CD summary*, August 5, 1997.
2. **Press, RD**. Exclusivity in testing for patented disease genes. *Mol Diagn* 4: 72-3, 1999.
3. **Press, RD**. Analyte-specific reagents. *Mol Diagn* 4: 71, 1999.
4. **Press, RD**. Clinical News Update. *Mol Diagn* 4: 163-5, 1999.
5. **Press, RD**. Hemochromatosis: a “simple” genetic trait. *Hospital Practice* 34: 55-74, 1999.
6. **Press, RD**. Subspecialty certification examination in molecular genetic pathology. *Mol Diagn* 4: 255, 1999.
7. **Press, RD**. Food and Drug Administration approval for 2 new molecular infectious disease assays. *Mol Diagn* 4: 256, 1999.
8. **Press, RD**. GeneClinics Medical Genetics Knowledge Base. *Mol Diagn* 4: 256, 1999.
9. **Press, RD**. Iron beware: a common HFE gene polymorphism may prevent the accurate molecular diagnosis of homozygous hemochromatosis in low-risk, but not high-risk groups. *Hepatology* 31: 540-42, 2000.
10. **Press, RD**. Overestimation of HFE C282Y homozygous hemochromatosis prevalence as the result of a common primer-binding site polymorphism. *Mol Diagn* 4: 391-2, 1999.
11. **Press, RD**. Thrombotic Risk Assessment. *Clinical Laboratory News*: January 2000, 8-12.
12. **Press RD**. Human Papillomavirus DNA detection for cervical cancer screening. *Mol Diagn* 5: 245-7, 2000.
13. **Press, RD**. Detection of prevalent genetic alterations predisposing to hemochromatosis and other common human diseases. *Clin Chem* 46: 1526-8, 2000.
14. **Press RD**. Thrombophilic mutations impart a high risk of pregnancy-related venous thrombosis. *Mol Diagn* 5: 158, 2000.

15. **Press RD.** Preliminary CLIAC recommendations to regulate genetic testing. *Mol Diagn* 5: 245-7, 2000.
16. **Press RD & Loeb C.** “Molecular Diagnostic Pathology” chapter, in *Essentials of Anatomic Pathology*, D Bostwick & L Chiang, editors, Humana Press, Totowa, NJ, 2002.
17. **Press RD.** Laboratory standards and guidelines for population-based cystic fibrosis carrier screening. *Mol Diagn* 6: 212-213, 2001.
18. **Press RD.** Crohn's disease is caused by mutations in the bacterial response protein NOD2. *Mol Diagn*. 6:347-8, 2001.
19. **Press RD.** Pharmacologic inhibition of the Bcr-Abl kinase with ST1571: a novel, safe, and effective therapy for chronic myeloid leukemia. *Mol Diagn* 6: 211-213, 2001.
20. **Press RD.** New Food and Drug Administration-based oversight over genetic testing. *Mol Diagn*. 6:348-9, 2001.
21. **Press RD.** Hemochromatosis caused by mutations in the iron-regulatory proteins ferroportin and H ferritin. *Mol Diagn*. 6:347, 2001.
22. **Press RD.** Chronic myeloid leukemia (CML): laboratory monitoring of minimal residual disease. *Clinical Laboratory News* (Dec. 2003).
23. J Kingery, GR Wettach, & **RD Press**, “Molecular Diagnostics” (chapter 2) in Wettach , Palmrose & Morgan, editors, USMLE Roadmap: Pathology , McGraw Hill, 2009.
24. Huang, J. & **Press RD**, “Molecular Diagnostic Pathology” (chapter 11), in *Essentials of Anatomic Pathology*, L Cheng & D Bostwick, ed., 3rd edition, Springer Press, New York, 2011.
25. Moore, F. & **Press RD**, “Molecular Pathology of Solid Tumors” (chapter 12), in *Essentials of Anatomic Pathology*, L Cheng & D Bostwick, ed., 3rd edition, Springer Press, New York, 2011.
26. Nucleic Acid Amplification Assays for Molecular Hematopathology; Approved Guideline (2nd edition). Clinical & Laboratory Standards Institute. CLSI document MM05-A2 (2012).